Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27215165 | 0.83 | TAAR1 (0.38) | TAAR1ALDH1A1CYP3A4TSHRALOX15 | |
| SCHEMBL29705432 | 0.83 | TAAR1 (0.38) | TAAR1ALDH1A1CYP3A4TSHRALOX15 | |
| SCHEMBL488488 | 0.82 | TAAR1 (0.39) | TAAR1TNFRIPK1 | |
| SCHEMBL1358925 | 0.78 | NOTUM (0.42) | TAAR1ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL16613034 | 0.78 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL10433184 | 0.78 | CA12 (0.37) | ALDH1A1CYP3A4TSHRALOX15SMN1; SMN2 | |
| SCHEMBL21076786 | 0.77 | DAO (0.36) | TAAR1ALDH1A1CYP3A4TSHRALOX15 | |
| SCHEMBL634584 | 0.76 | ALDH1A1 (0.36) | TAAR1ALDH1A1 | |
| SCHEMBL23088480 | 0.75 | CA12 (0.34) | TAAR1ALDH1A1CYP3A4TSHRALOX15 | |
| SCHEMBL18797700 | 0.75 | CYP1A2 (0.32) | TAAR1TNFRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2592083-A1 | FUSED QUINAZOLINE DERIVATIVES AND USES THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2013-05-15 | — | — | EP | disclosed |
| US-20110288086-A1 | POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288086-A1 | POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF | AURKA, AURKC, AURKB | TAAR1 4677/4885ALDH1A1 3950/4885CYP3A4 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.